Author: Arvanitidis, Konstantinos ; Drygiannakis, Ioannis ; Paspaliaris, Vasilis ; Bamias, Giorgos ; Spathakis, Michail ; Kokkotis, Georgios ; Valatas, Vassilis ; Manolopoulos, Vangelis G ; Vradelis, Stergios ; Kandilogiannakis, Leonidas ; Dovrolis, Nikolas ; Tarapatzi, Gesthimani ; Filidou, Eirini ; Kolios, George

AbstractBackgroundOncostatin-M (OSM) is associated with antitumor necrosis factor (anti-TNF)-α resistance in inflammatory bowel disease (IBD) and fibrosis in inflammatory diseases. We studied the expression of OSM and its receptors (OSMR, gp130) on intestinal subepithelial myofibroblasts (SEMFs) and the effect of OSM stimulation on SEMFs.MethodsThe mRNA and protein expression of OSM, OSMR, gp130, and several fibrotic and chemotactic factors were studied in mucosal biopsies and isolated human intestinal SEMFs of patients with IBD and healthy controls (HCs) and in a model of human intestinal organoids (HIOs). Subepithelial myofibroblasts and HIOs were stimulated with OSM and interleukin (IL)-1α/TNF-α. RNAseq data of mucosal biopsies were also analyzed.ResultsOncostatin-M receptors and gp130 were overexpressed in mucosal biopsies of patients with IBD (P < .05), especially in inflamed segments (P < .05). The expression of OSM, OSMR, and gp130 in SEMFs from HCs was increased after stimulation with IL-1α/TNF-α (P < .001; P < .01; P < .01). The expression of CCL2, CXCL9, CXCL10, and CXCL11 was increased in SEMFs from patients with IBD and HCs after stimulation with OSM in a dose-dependent manner (P < .001; P < .05; P < .001; P < .001) and was further increased after prestimulation with IL-1α/TNF-α (P < .01 vs OSM-alone). Similar results were yielded after stimulation of HIOs (P < .01). Oncostatin-M did not induce the expression of collagen I, III, and fibronectin. Oncostatin-M receptor expression was positively correlated with CCL2, CXCL9, CXCL10, and CXCL11 expression in mucosal biopsies (P < .001; P < .001; P = .045; P = .033).ConclusionsHuman SEMFs overexpress OSMR in an inflammatory microenvironment. Oncostatin-M may promote inflammation in IBD via its stimulatory effects on SEMFs, which primarily involve chemoattraction of immune cells to the intestinal mucosa.

01 Oct 2024·Journal of Endocrinology

Oncostatin M: friend or foe in PCOS pathogenesis

Review

Author: Oghbaei, Farnaz ; Fattahi, Amir ; Khodavirdilou, Rasa ; Laleh, Sanya Hayati ; Amorim, Christiani A. ; Latifi, Zeinab ; Nejabati, Hamid R. ; Zarezadeh, Reza ; Nikanfar, Saba ; Khodavirdilou, Lida

Polycystic ovary syndrome (PCOS) is a primary endocrinological disorder in women of reproductive age that is characterized by androgen excess and ovulatory irregularities. This syndrome is associated with adipose tissue dysfunction, an elevated risk of insulin resistance, hyperinsulinemia, obesity, and type 2 diabetes. Adipocyte dysfunction affects the secretion of adipokines and pro-inflammatory cytokines. Nevertheless, adipose tissue is not an exclusive source of adipokines as it can also be produced locally by reproductive tissues. Although adipokines have been recognized in the development of PCOS, the role of oncostatin M (OSM), a multifaceted adipokine, remains unclear. Current evidence suggests that this cytokine is associated with key aspects of the syndrome, including obesity, insulin resistance, hyperandrogenism, and inflammation. However, the data are often contradictory, likely due to variations in study designs, methodologies, and species differences. By investigating the link between OSM and PCOS-associated issues, this review identified the potential role of this adipokine in PCOS pathogenesis. This underscores the need for further research to clarify its predominant effects and assess its relevance as a therapeutic target.

100 Deals associated with Oncostatin M

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Neovascularization	Preclinical	DE	University of Freiburg	01 May 2022
Immunologic Deficiency Syndromes	Discovery	US	Bristol Myers Squibb Co.	-
Neoplasms	Discovery	US	Bristol Myers Squibb Co.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EASD2022	Not Applicable	-	-	oncostatin-M	mqyhdrysqe(hhfwuqcwod) = +47% pejwqfdxzd (szahkcrsxx ) View more	Positive	21 Sep 2022
				oncostatin-M
UEGW2019	Not Applicable	Inflammatory Bowel Diseases	-	Oncostatin M (Treatment-naive newly diagnosed IBD patients)	hptzsbgjdq(cbfygplbbr) = nfrwiwvmwl urbardlvrt (cgxxywgmng, 3.7E - 09) View more	-	01 Oct 2019
				Anti-TNF cohort	hptzsbgjdq(cbfygplbbr) = knfsozoogi urbardlvrt (cgxxywgmng, 5.0E - 02)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Oncostatin M

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation